GCAN 10-K & 10-Q changes, risk factors and insider trading
Trafalgar International, Inc. (also GCAND) · Pharmaceutical Preparations · CIK 1695473 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
As a “smaller reporting company” as defined in Rule 12b-2 under the Exchange Act, disclosure of this Item is not required.
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
No wording changes found in this section (only numbers or dates changed in 6 paragraphs).
Full comparison: every changed paragraph (0)
What changed in the latest 10-Q
Risk Factors
As a “smaller reporting company” as defined in Rule 12b-2 under the Exchange Act, disclosure of this Item is not required.
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
New heading “See Note-A-Nature of Operations - Change in Control.”
Largest changes
“Following the change in control completed on June 29, 2026, the Company commenced a transition to a broader business strategy focused on acquiring, developing and growing businesses in the financial services, technology and intellectual property sectors. The Company intends to pursue this strategy through acquisitions, direct investments, joint ventures, licensing arrangements and other strategic transactions and business development opportunities.”see in full comparison
“The Company’s current business plan is to (i) conduct clinical studies on and commercialize the cannabinoid-based therapeutic and (ii) concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions.”see in full comparison
Other income and (expenses) wassee in full comparison$0$642,933 for thethreesix months endedMarchJune31,30, 2026, as compared to $(59,975541,483) for the same quarter in 2025. The increasedecreasein income is duefromtolosstheon conversioncancellation ofnotes payabledebt in the amount of$57,920$621,450 and cancellation of preferred stock B in theyearamount2025.of $21,483.
Our netsee in full comparisonlossincome for thethreesix months endedMarchJune31,30, 2026, was$33,376$598,004 as compared to the net loss of$103,511$633,270 during the same quarter in 2025.
Our operating expenses in thesee in full comparisonthreesix months endedMarchJune31,30, 2026 decreased to$33,376,$44,929, from$43,536$91,787 for the same period of 2025. Major operating expenses include officers compensation of $30,000, amortization expense, professional fees and research and development costs.
Full comparison: every changed paragraph (10)
Following the change in control completed on June 29, 2026, the Company commenced a transition to a broader business strategy focused on acquiring, developing and growing businesses in the financial services, technology and intellectual property sectors. The Company intends to pursue this strategy through acquisitions, direct investments, joint ventures, licensing arrangements and other strategic transactions and business development opportunities.
See Note-A-Nature of Operations - Change in Control.
The
Company’s current business plan is to (i) conduct clinical studies on and commercialize the cannabinoid-based therapeutic and (ii)
concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing
agreements or acquisitions.
The
Company had no revenue during each of the three and six months ended MarchJune 31,30, 2026 and 2025.
Our
operating expenses in the threesix months ended MarchJune 31,30, 2026 decreased to $33,376,$44,929, from $43,536$91,787 for the same period of 2025. Major operating
expenses include officers compensation of $30,000, amortization expense, professional fees and research and development costs.
Other
income and (expenses) was $0$642,933 for the threesix months ended MarchJune 31,30, 2026, as compared to $(59,975541,483) for the same quarter in 2025. The
increase decrease
in income is due fromto lossthe on conversioncancellation of notes payabledebt in the amount of $57,920$621,450 and cancellation of preferred stock B in the yearamount 2025.of
$21,483.
Our
net lossincome for the threesix months ended MarchJune 31,30, 2026, was $33,376$598,004 as compared to the net loss of $103,511$633,270 during the same quarter in 2025.
We
had $1,439$111 cash at MarchJune 31,30, 2026, compared to $815 cash at December 31, 2025.
At
MarchJune 31,30, 2026 and December 31, 2025 we had $268,600$0 and 263,600 in loans payable to related parties.
The
following table provides detailed information about our net cash flows for the threesix months ended MarchJune 31,30, 20252026 and 2024.2025.
GCAN insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
No Form 4 stock transactions in this period.
Well-known investors holding GCAN (13F)
None of the 59 investors we track reported a position in their latest 13F.